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ABSTRACT 
Objectives. We investigated renal 
outcome of kidney-transplantation in 
Korean recipients with biopsy-proven 
renal involvement of antineutrophil cy-
toplasmic antibody (ANCA)-associated 
vasculitis (AAV) in a single centre.
Methods. We reviewed the medical 
records of 144 Korean patients and 
included 3 female patients with mi-
croscopic polyangiitis (MPA) and one 
male patient with eosinophilic granu-
lomatosis with polyangiitis (EGPA) in 
this study. We obtained clinical and 
laboratory data related to kidney-
transplantation, analysed renal out-
come of kidney-transplantation in 4 re-
cipients with AAV and compared it with 
those of previous studies.
Results. The mean age at diagnosis 
was 37.8 years and that at kidney-
transplantation was 40.8 years. Time-
gap from AAV to ESRD ranged from 1 
to 48 months and that from AAV to kid-
ney-transplantation ranged from 2 to 
95 months. All kidney-recipients with 
had been followed-up for two years or 
greater. At diagnosis, MPO-ANCA was 
detected in only MPA patients, while, at 
transplantation, MPA-ANCA was de-
tected in 2 MPA patients and an EGPA 
patient. All patients have received tac-
rolimus and mycophenolate mofetil 
based on glucocorticoid after kidney-
transplantation. Among 4 kidney-recip-
ients with AAV, one MPA patient under-
went renal re-biopsies three times due 
to renal function deterioration during 
the follow-up. Renal histology revealed 
T cell-mediated and antibody-mediated 
rejection rather than relapse of MPA. 
Neither relapse nor graft failure was 
observed in our study. 
Conclusion. Renal outcome of kidney- 
transplantation in recipients with AAV 
was good and kidney-transplantation 
is deserved to be recommend as a safe 
and effective therapeutic modality to 
AAV patients with ESRD. 
Introduction
Antineutrophil cytoplasmic antibody 
(ANCA)-associated vasculitis (AAV) 
is a group of systemic necrotising vas-
culitides, which mainly encroach small 
vessels from capillaries to arterioles 
(1). AAV generally consists of 3 vari-
ants based on clinical and histological 
features including microscopic poly-
angiitis (MPA), granulomatosis with 
polyangiitis (GPA, identical to Wegen-
er’s granulomatosis) and eosinophilic 
GPA (EGPA, identical to Churg-Strauss 
syndrome) (1-5). The frequency of re-
nal involvement of AAV depends on 
variants: 90–100% in MPA, 50–80% in 
GPA, 31–51% in ANCA positive EGPA 
and 4–16% ANCA negative EGPA (6). 
Most common histological feature of 
renal involvement of AAV is pauci-im-
mune crescentic and/or necrotising glo-
merulonephritis, leading to rapid pro-
gressive glomerulonephritis (7). Renal 
involvement of AAV may result in end 
stage renal disease (ESRD) in 20-40% 
of AAV patients (8-10), and kidney 
transplantation has been considered a 
suitable therapeutic modality and more 
valuable benefits than maintenance of 
dialysis (11, 12). So far, histological 
features, age, glomerular filtration rate 
and PR3-ANCA at kidney transplanta-
tion were reported to be poor prognos-
tic factors (13, 14). Despite a relatively 
low rate (0.02/patient year) of relapse 
of AAV after kidney-transplantation, 
because no guideline for kidney-trans-
plantation in AAV patients with ESRD 
is recommended optimal timing and 
indication of kidney-transplantation 
and risk factors for relapse of AAV 
after kidney-transplantation, we still 
have concerns over the adverse effects 
of relapse on both graft- and patient-
survival (8). Moreover, there was no 
report regarding renal outcome of kid-
ney-transplantation in recipients with 
AAV in Korea. Hence, in this study, we 
investigated renal outcome of kidney-
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transplantation in Korean recipients 
with biopsy-proven renal involvement 
of AAV in a single centre.
Materials and methods
Patients
We retrospectively reviewed the details 
of the electrical medical records of 144 
Korean patients according to the inclu-
sion criteria as the follows: i) patients 
who were first classified as MPA, GPA 
or EGPA from October 2000 to July 
2017 at Division of Rheumatology, De-
partment of Internal Medicine, Yonsei 
University College of Medicine, Sever-
ance hospital; ii) those who were clas-
sified according to the 1990 American 
College of Rheumatology (ACR) clas-
sification criteria for GPA and EGPA, 
the 2007 European Medicines Agency 
(EMA) algorithm and the 2012 revised 
Chapel Hill Consensus Conference 
Nomenclature of Vasculitides (1-4); 
iii) those who had results of myeloper-
oxidase (MPO)-ANCA and proteinase 
3 (PR3)-ANCA at diagnosis and kid-
ney-transplantation; vi) those who had 
biopsy-proven pauci-immune based 
crescentic and/or necrotising glomeru-
lonephritis (7); v) those who had ESRD 
due to AAV, but not due to other mean-
ingful medical conditions to accelerate 
progression to ESRD, such as diabetes 
mellitus, refractory hypertension, viral 
hepatitis, autoimmune diseases other 
than AAV; vi) those who underwent 
kidney-transplantation at Severance 
hospital after January 2005 and who 
had been followed-up for two years or 
greater; vii) those who had received 
prednisolone, mycophenolate mofetil 
and tacrolimus based on the same proto-
col suggested by Department of Trans-
plantation Surgery after January 2005; 
viii) those who had well-written medi-
cal records at diagnosis, around kidney-
transplantation and during the follow-
up to identify clinical progress. Medical 
conditions were searched by the 10th 
revised International Classification of 
Diseases (ICD-10) and medications 
administered were monitored under the 
Korean Drug Utilization Review (DUR) 
system. Five patients fulfilled the inclu-
sion criteria, but one patient had been 
followed-up for only two months. Fi-
nally, we included four patients in this 
study and investigated renal outcome 
of kidney-transplantation in 4 Korean 
recipients with biopsy-proven AAV in a 
single centre. This study was approved 
by the institutional Review Board of 
Severance Hospital (4-2016-0901).
Clinical and laboratory data 
and AAV classification 
We collected age at diagnosis and age 
at kidney-transplantation and gender as 
demographic data. We also collected 
time-gap from diagnosis of AAV to 
ESRD and time-gap from diagnosis of 
AAV to kidney-transplantation. We ob-
tained the results of MPO-ANCA and 
PR3-ANCA not only at diagnosis, but 
also at kidney-transplantation. We also 
obtained renal histological features at 
diagnosis. We applied sequentially the 
1990 ACR criteria for EGPA and GPA 
and the 2007 EMA algorithm modified 
by the 2012 CHCC definitions to study 
subjects as described in Table I (1-4). 
Data related to kidney-transplantation
We reviewed the medical records re-
lated to kidney-transplantation regard-
ing kidney donor, therapeutic regimens 
based glucocorticoid after kidney-trans-
plantation, rejection, relapse of AAV, 
graft failure and CKD stage at present. 
Graft failure was defined as a status 
which needs to restart dialysis therapy 
or re-transplantation and death due to 
renal and non-renal cause (9, 15). Pa-
tients with unexplained elevated serum 
creatinine (greater than 30% increase 
over baseline), increased proteinuria 
(greater than 0.5g/day), and persistent 
haematuria (>5 RBC/HPF) were sub-
jected to renal biopsy (7, 9, 16). Acute 
rejection was defined when histological 
features exhibited one of three charac-
ters: acute T cell-mediated rejection, 
acute antibody-mediated rejection and 
acute vascular rejection (17). Relapse 
was defined as recurrence or new onset 
of disease attributable to active vascu-
litis (18). 
Literature review 
We selected 4 studies with a consid-
erable number of kidney-recipients 
with AAV from Western countries and 
case-reports from North-Eastern Asian 
countries with similar ethnicity to Ko-
rea, Japan and China. We also com-
pared renal outcome between our study 
and previous studies. 
Results
Baseline characteristics of 4 kidney-
recipients with AAV classified by the 
1990 ACR classification criteria and 
the 2007 EMA algorithm modified by 
the 2012 CHCC definitions
Our study included three female kid-
ney-recipients with MPA and the mean 
age at diagnosis and that at kidney-
transplantation were 43.7 year and 
45.0 years. All MPA patients did not 
fulfil the 1990 ACR criteria for EGPA 
or GPA. All MPA patients exhibited 
pauci-immune crescentic and/or ne-
crotising glomerulonephritis and had 
MPO-ANCA. Because they showed 
no granulomatosis on histology, or no 
GPA surrogate markers, they could be 
classified as MPA. Our study included 
only one male kidney-recipient with 
EGPA, who had been classified by the 
1990 ACR classification criteria with 
items of asthma, eosinophilia, periph-
eral neuropathy, paranasal sinusitis and 
extravasation of eosinophils on histol-
ogy. He had been diagnosed at 20 years 
of age and he underwent kidney-trans-
plantation at 28 years of age. He had 
neither MPO-ANCA nor PR3-ANCA. 
Renal outcome of kidney
transplantation in 4 recipients 
with AAV
Renal outcome of 4 kidney-recipients 
with AAV is shown in Table II.
Time-gap from diagnosis of AAV to 
ESRD ranged from 1 to 48 months 
and that from diagnosis of AAV to 
kidney-transplantation ranged from 
2 to 95 months. All kidney-recipients 
with AAV had been followed-up for 
two years or greater. On histology, two 
MPA patients exhibited pauci-immune 
crescentic and necrotising glomeru-
lonephritis and one MPA patients ex-
hibited pauci-immune crescentic glo-
merulonephritis. One EGPA patient 
exhibited extravasation of eosinophils 
along with pauci-immune crescentic 
glomerulonephritis. All patients re-
ceived kidney from living related donor 
(LRD). MPO-ANCA was detected in 
all MPA patients at diagnosis, but it was 
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detected in only two of three MPA pa-
tients at kidney-transplantation. Mean-
while, MPO-ANCA was not detected in 
an EGPA patient at diagnosis, but it was 
detected at kidney-transplantation. All 
patients have received tacrolimus and 
mycophenolate mofetil based on glu-
cocorticoid after kidney-transplantation 
according to the same protocol suggest-
ed by Department of Transplantation 
Surgery after January 2005. Among 4 
kidney-recipients with AAV, one MPA 
patient exhibited the increased amount 
of proteinuria and the deterioration in 
renal function. Finally she underwent 
re-biopsy of kidney three times dur-
ing the follow-up. Renal histology by 
three re-biopsies revealed T cell-medi-
ated and antibody-mediated rejection. 
Therefore, on the basis of histological 
features, we attributed the aetiology of 
aggravation of renal function to rejec-
tion rather than MPA. Plasmapheresis 
and glucocorticoid pulse therapy were 
performed for rapid kidney allograft 
dysfunction as induction therapy, and 
then tacrolimus and mycophenolate 
mofetil along with glucocorticoid were 
administered. Although three-time re-
jections provoked no graft failure, renal 
function deteriorated up to CKD stage 
IV though three-time rejections.
 Literature reviews and comparison 
of renal outcome between this study 
and previous studies
We reviewed previous studies investi-
gating renal outcome of kidney-trans-
plantation in a large number of AAV 
patients described in Table III. A study 
with 113 kidney-recipients with AAV 
in the Netherlands reported the median 
time-gap from kidney-transplantation 
to relapse of AAV of 22 months, 5 year-
graft-survival rate of 83% and 5 year-
patient-survival of 95% (19). A study 
with 93 kidney-recipients with AAV 
in Australia and New Zealand reported 
that MPA showed the worse renal out-
Table I. Baseline characteristics of 4 kidney-recipients with AAV classified by the 1990 ACR classification criteria and the 2007 EMA 
algorithm modified by the 2012 CHCC definitions.
Patients Gender/ Age at kidney ANCA ACR for EGPA ACR for GPA Histology Histology No histology Clinical and
 Age at  transplantation    compatible compatible GPA surrogate histologic
 diagnosis     with 2012 with 2012 markers and evidence of
      revised CHCC revised CHCC PR3- or MPO- small-vessel
      GPA MPA and GPA ANCA vasculitis
       surrogate positivity No GPA
       markers  surrogate 
         markers
    EGPA GPA GPA GPA GPA MPA
1 F/33 33 MPO-ANCA NO NO NO NO NO YES
2 F/40  41 MPO-ANCA NO NO NO NO NO YES
3 F/58  61 MPO-ANCA NO NO NO NO NO YES
4 M/20  28 ANCA negative YES*     
*YES: asthma, sinusitis, eosinophilia and peripheral neuropathy; pauci-immune crescentric glomerulonephritis. 
AAV: ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic antibody; ACR: American College of Rheumatology; EMA: European Medicine Agency; CHCC: Chapel 
Hill Consensus Conference; EGPA: eosinophilic granulomatosis with polyangiitis; GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; PR3: proteinase 3; 
MPO: myeloperoxidase.  
Table II. Renal outcome of kidney-transplantation in 4 recipients with AAV.
Patients Time-gap Time-gap from Follow-up Histological  Kidney ANCA  Therapeutic Rejection Relapse Graft Renal
(AAV from AAV AAV to kidney- duration features donor at kidney- regimens   failure Function
variants) to ESRD transplantation after kidney-   transplantation based on    (CKD
 (months)  (months) transplantation    glucocorticoid    stage)
   (months)    after kidney-      
       transplantation   
 
1 (MPA) 29 32 33 pauci-immune LRD MPO-ANCA tacrolimus and NO NO NO CKD I
    crescentic and  positive mycophenolate 
    necrotising   mofetil
    glomerulonephritis    
2 (MPA) 1 2 28 pauci-immune LRD MPO-ANCA tacrolimus and NO NO NO CKD III
    crescentic  positive mycophenolate
    glomerulonephritis   mofetil
    with interstitial
    nephritis    
3 (MPA) 23 37 60 pauci-immune LRD ANCA tacrolimus and YES NO NO CKD IV
    crescentic and  negative mycophenolate
    necrotising   mofetil
    glomerulonephritis    
4 (EGPA) 48 95 126 pauci-immune LRD MPO-ANCA tacrolimus and NO NO NO CKD I
    crescentic  positive mycophenolate
    glomerulonephritis   mofetil
    extravasation
    of eosinophils    
AAV: ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic antibody; ESRD: end stage renal disease; CKD: chronic kidney disease; MPA: microscopic polyangiitis; 
EGPA: eosinophilic granulomatosis with polyangiitis; LRD: living related donor; MPO: myeloperoxidase. 
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come than GPA in both graft-survival 
and patient-survival (50% at 10 years 
for MPA vs. 62% at 10 years for GPA, 
and 68% at 10 years for MPA vs. 85% 
at 10 years for GPA, respectively) (20). 
A study with 85 kidney-recipients with 
AAV in United States of America (USA) 
provided more concrete information on 
relapse of AAV represented as vasculi-
tis relapse per patient year of 0.02 for 
the follow-up of 64 months and time-
gap from kidney-transplantation to re-
lapse of 29.6 months. Furthermore, it 
reported the better overall 10 year-graft 
survival than a study in Australia and 
New Zealand (79% vs. 50% for MPA 
and 62% for GPA), but similar 10 year-
patient survival (21). Another study 
with 107 kidney-recipients with AAV 
in the United Kingdom (UK) provided 
the similar renal outcome to the results 
of a study conducted in USA including 
vasculitis relapse per patient year of 
0.01 for the follow-up of 66 months, 10 
year-graft survival of 70% and 10 year-
patient survival of 65% (22).
There must be ethnic differences in 
both graft-survival and patient-survival 
between kidney-recipients with AAV in 
Western and North-Eastern Asian coun-
tries (23). However, as far as I know, 
there were only several case reports. 
Renal outcomes of kidney-transplanta-
tion in two Japanese kidney-recipients 
with AAV were reported. A 21 year-old 
recipient exhibited neither relapse of 
AAV nor graft failure during the fol-
low-up of 48 months, while a 57 year-
old recipient showed relapse of AAV at 
12 months after kidney-transplantation, 
leading to graft failure (24, 25). Renal 
outcome of kidney-transplantation in 
one Chinese recipient with AAV was 
also reported. This recipient immedi-
ately experienced relapse of AAV at 4 
days after kidney-transplantation and 
underwent plasma exchange. Fortu-
nately, despite relapse of AAV, no graft 
failure was observed during the follow-
up of 5 months (26).
Our study included the more number 
of kidney-recipients and followed them 
up for the longer period than previous 
reports in Japan and China. Further-
more, renal outcome of kidney-trans-
plantation was better that that of Japa-
nese cases: neither relapse of AAV nor 
graft failure were observed during the 
follow-up of 61.8 months. 
Discussion
In this study, we first reported renal 
outcome of kidney-transplantation in 
Korean recipients with biopsy-proven 
renal involvement of AAV in a single 
centre. Of 144 patients with AAV, 5 
patients underwent kidney-transplanta-
tion due to ESRD related to AAV, but 
we included only 4 kidney-recipients 
with AAV, who had been followed-up 
for two years or greater (3 MPA and 1 
EGPA patients). Four patients exhib-
ited a relatively long time-gap between 
diagnosis of AAV to ESRD of 25.3 
months and that between diagnosis of 
AAV to kidney-transplantation of 41.5 
months. During a considerable period 
of follow-up, one kidney-recipient un-
derwent renal re-biopsy due to allograft 
rejection, but not relapses of MPA, on 
the basis of histopathological features 
of kidney tissues. We suggest that phy-
sicians should not hesitate to consider 
kidney-transplantation as one of renal 
replacement modalities in AAV pa-
tients, whose renal function deteriorates 
to ESRD, with concerns over relapse of 
AAV or graft failure.
A recent review described the dis-
crepancies in clinical phenotypes and 
outcomes of AAV patients in Japan 
compared to those in the UK such as 
older at disease onset, less PR3-ANCA 
positivity, milder renal dysfunction and 
more frequent respiratory involvement 
(27). 
Due to lack of data regarding renal out-
come of kidney-transplantation in AAV 
recipients from North-Eastern Asian 
countries, we inevitably analysed renal 
outcome in those from Western coun-
tries and we learned several issues: 
first, relapse of AAV can occur regard-
less of the presence of graft failure (19, 
21, 22). Thus, kidney-transplantation 
Table III. Literature reviews and comparison of renal outcome between this study and previous studies.
Authors Nation Number of  Transplant Follow-up Vasculitis Time-gap Graft survival Patient survival
(reference number)   kidney- years or duration relapse from KT
  recipients age after KT per patient to relapse
    (months) year   (months) 
Göçeroğlu A, et al. (17) Netherlands 113 1984-2011 NA NA Median 22 95% at 1 year and 83% at 5 years 95% at 5 years
Tang et al. (18) Australia and 93 1996-2010 NA NA  82% at 5 years and 50% 82% at 5years and 68%
 New Zealand      at 10 years (MPA) at 10 years (MPA) 
       96% at 5 years and 62% 96% at 5 years and 85% 
       at 10 years (GPA)  at 10 years (GPA)
Geetha D, et al. (19) USA 85 1996-2010 64 0.02 29.6 (2-55) 100% at 1 year, 97.9% at 5 years 100% at 1 year, 93.4% at 5 years
       and 79% at 10 years and 67.4% at 10 years
Little MA, et al. (20) UK 107 1965-2005 66 0.01 NA 90% at 5 years and 70% 90% at 5 years and 65% at 10 years 
       at 10 years 
Kaseda K, et al. (22) Japan 1 21 years 48 0  100% 100%
Tabata H, et al. (23) Japan 1 57 years NA 1 12 0% 100%
Sun Q, et al. (24) China 1 2006 5 1 4 days  100% 100%
      after KT 
Park ES, et al. Republic  4 33, 41, 61 61.8 NA NA 100% 100%
 of Korea  and 28 years 
KT: kidney-transplantation; USA: United States of America; UK: United Kingdom; NA: not applicable; MPA: microscopic polyangiitis; GPA: granulomatosis with polyangiitis. 
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is recommended to be performed after 
a sufficient period from the achieve-
ment of remission without a contrain-
dication by ANCA positivity at kidney-
transplantation (11). Relapse was more 
frequent in the first 2 years with differ-
ences in its frequency according vari-
ants: GPA (up to 60%), EGPA (35%) 
and MPA (8%) (10). Also cyclophos-
phamide or rituximab can be still neces-
sary for treating post-transplant relapse 
of AAV despite immunosuppressive 
agents such as tacrolimus or mycophe-
nolate mofetil based on glucocorticoids 
(11). Although, there was no relapse in 
our study, we realise the need for se-
rial assessment of vasculitis activity 
and titres of ANCAs with a short-term 
follow-up schedule. Second, given that 
AAV recurrence was observed in small 
number of renal allografts (2%) (20), 
both reduced graft-survival and patient-
survival rates mainly result from acute 
or chronic rejection, but not relapse of 
AAV. Third, MPA exhibits the rapider 
progression to graft failure (Hazard ratio 
1.87) and the higher mortality (Hazard 
ratio of 1.94) than GPA at 10 years after 
kidney-transplantation (20). Returning 
to data from North-Eastern Asian coun-
tries, Japanese kidney-recipients with 
AAV exhibited graft-survival of 50%, 
while Chinese kidney-recipient with 
AAV exhibited graft-survival of 100%. 
However, because these reports includ-
ed only one recipient per each case-re-
port and two of three case-reports ob-
served relapse of AAV and graft failure 
within 12 months. On the other hands, 
our study included 4 kidney-recipients 
among 144 AAV patients and observed 
renal outcome for at least more than 2 
years. By contrast with studies from 
Western countries, our study showed 
no relapse, no graft failure and further-
more, no difference in graft-survival 
and patient-survival rates between MPA 
and EGPA. However, there were three 
cases of rejection in one patient with 
MPA. Thus, we conclude that kidney-
transplantation is a safe and effective 
therapeutic method for AAV patients 
with ESRD under the administration of 
tacrolimus or mycophenolate mofetil 
based on glucocorticoids, which can 
provide therapeutic benefit for prevent-
ing relapse of MPA.
Cyclophosphamide or rituximab along 
with glucocorticoid are currently rec-
ommended as the induction therapeutic 
regimens (28-30). Once remission is 
achieved, azathioprine, methotrexate 
and mycophenolate mofetil and/or glu-
cocorticoid are suggested as the mainte-
nance therapeutic regimens (6, 31). On 
the other hands, the combination thera-
py of calcineurin inhibitors such as tac-
rolimus and sirolimus, and mycopheno-
late mofetil based on glucocorticoids, 
which has a selective mechanism for T 
and B cell post-transplantation immune 
modulation, has been recommended 
as post-transplantation maintenance 
therapeutic regimens until now (32). 
This combination therapy has increased 
both graft-survival and patient-survival 
rates, and reduced the opportunity of 
infection by (33). Furthermore a com-
bination therapy of tacrolimus and 
mycophenolate mofetil and/or gluco-
corticoid, modulating both T and B 
cells, might be sufficient to maintain 
remission or low vasculitis activity af-
ter kidney-transplantation. Thus, we 
conclude that a combination therapy of 
tacrolimus and mycophenolate mofetil 
and/or glucocorticoid may reduce the 
rate of relapse of AAV, resulting in the 
low frequency of graft failure.
We wonder how we could affirm that 
the deterioration in renal function and 
three time-renal re-biopsies were due to 
allograft rejection rather than relapse of 
AAV in patient 3. We have two reasons 
beyond histological features: first, high 
titre of circulating ANCA at kidney-
transplantation is associated with re-
lapse of AAV during the follow-up after 
kidney-transplantation (22). Patient 3 
exhibited ANCA positivity at diagnosis 
of AAV, however, ANCA negativity at 
kidney-transplantation. Thus, the pos-
sibility of relapse of AAV is relatively 
low. Second, patient 3 did not exhibit 
other extra-renal manifestations, which 
she had exhibited at diagnosis of AAV. 
Therefore, we affirm that patient 3 ex-
perience acute and chronic allograft re-
jection rather than relapse of AAV.
Our study has a strong merit that we 
first reported renal outcome of kidney-
transplantation in recipients with AAV 
with a considerable follow-up dura-
tion after kidney-transplantation. Par-
ticularly, because all kidney-recipients 
received immunosuppressive drugs 
according to a controlled protocol in a 
single centre, we could minimise the 
confounding factors depending on ther-
apeutic regimens. However, our study 
also has several issues. First, due to the 
limited number of kidney-recipients 
with AAV, the different follow-up dura-
tion as well as timing of kidney trans-
plantation, our study could provide 
neither the general conclusion with sta-
tistical significance nor the right time 
to perform kidney transplantation after 
diagnosis. However, considering geo-
graphical and ethnic variations between 
Western and North-Eastern Asian coun-
tries, our study might have the clini-
cal implication that it could provide a 
therapeutic potential of kidney trans-
plantation in Korean AAV patients with 
ESRD including North-Eastern Asian 
countries. Second, due to the retrospec-
tive study-design, we could not provide 
the serial and protocol-based assess-
ment of vasculitis activity and titres of 
ANCAs during the follow-up for the 
right timing of kidney transplantation 
to improve the graft survival. Last, be-
cause the kidney-recipients with AAV 
in our study were too heterogeneous to 
hypothesise the AAV variant-specific 
mechanism and furthermore no patients 
with GPA underwent kidney-transplan-
tation, we could not elucidate renal 
outcome of kidney-recipients based on 
each variant of AAV. If future studies 
can prospectively and serially assess 
protocol-based vasculitis activity and 
titres of ANCAs, they could provide 
valuable and dynamic information of 
renal outcome of kidney-transplanta-
tion in recipients with AAV during the 
long-term follow-up. In conclusion, 
renal outcome of kidney- transplanta-
tion in recipients with AAV was good 
and kidney-transplantation is deserved 
to be recommend as a safe and effective 
therapeutic modality to AAV patients 
with ESRD. 
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